Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
Background - Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 September 2010
|
| In: |
The lancet. Oncology
Year: 2010, Jahrgang: 11, Heft: 11, Pages: 1057-1065 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(10)70206-0 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(10)70206-0 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204510702060 
|
| Verfasserangaben: | Annemiek Broyl, Sophie L Corthals, Joost LM Jongen, Bronno van der Holt, Rowan Kuiper, Yvonne de Knegt, Mark van Duin, Laila el Jarari, Uta Bertsch, Henk M Lokhorst, Brian G Durie, Hartmut Goldschmidt, Pieter Sonneveld |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1837854092 | ||
| 003 | DE-627 | ||
| 005 | 20230710154720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230301s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(10)70206-0 |2 doi | |
| 035 | |a (DE-627)1837854092 | ||
| 035 | |a (DE-599)KXP1837854092 | ||
| 035 | |a (OCoLC)1389821477 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Broyl, Annemiek |e VerfasserIn |0 (DE-588)1222999919 |0 (DE-627)1742283594 |4 aut | |
| 245 | 1 | 0 | |a Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma |b a prospective analysis of data from the HOVON-65/GMMG-HD4 trial |c Annemiek Broyl, Sophie L Corthals, Joost LM Jongen, Bronno van der Holt, Rowan Kuiper, Yvonne de Knegt, Mark van Duin, Laila el Jarari, Uta Bertsch, Henk M Lokhorst, Brian G Durie, Hartmut Goldschmidt, Pieter Sonneveld |
| 264 | 1 | |c 21 September 2010 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.03.2023 | ||
| 520 | |a Background - Bortezomib-induced peripheral neuropathy is a dose-limiting toxicity in patients with multiple myeloma, often requiring adjustment of treatment and affecting quality of life. We investigated the molecular profiles of early-onset (within one treatment cycle) versus late-onset (after two or three treatment cycles) bortezomib-induced peripheral neuropathy and compared them with those of vincristine-induced peripheral neuropathy during the induction phase of a prospective phase 3 trial. - Methods - In the induction phase of the HOVON-65/GMMG-HD4 trial, patients (aged 18-65 years) with newly diagnosed Salmon and Durie stage 2 or 3 multiple myeloma were randomly assigned to three cycles of bortezomib-based or vincristine-based induction treatment. We analysed the gene expression profiles and single-nucleotide polymorphisms (SNPs) of pretreatment samples of myeloma plasma cells and peripheral blood, respectively. This study is registered, number ISRCTN64455289. - Findings - We analysed gene expression profiles of myeloma plasma cells from 329 (39%) of 833 patients at diagnosis, and SNPs in DNA samples from 369 (44%) patients. Early-onset bortezomib-induced peripheral neuropathy was noted in 20 (8%) patients, and 63 (25%) developed the late-onset type. Early-onset and late-onset vincristine-induced peripheral neuropathy was noted in 11 (4%) and 17 (7%) patients, respectively. Significant genes in myeloma plasma cells from patients that were associated with early-onset bortezomib-induced peripheral neuropathy were the enzyme coding genes RHOBTB2 (upregulated by 1·59 times; p=4·5×10−5), involved in drug-induced apoptosis, CPT1C (1·44 times; p=2·9×10−7), involved in mitochondrial dysfunction, and SOX8 (1·68 times; p=4·28×10−13), involved in development of peripheral nervous system. Significant SNPs in the same patients included those located in the apoptosis gene caspase 9 (odds ratio [OR] 3·59, 95% CI 1·59-8·14; p=2·9×10−3), ALOX12 (3·50, 1·47-8·32; p=3·8×10−3), and IGF1R (0·22, 0·07-0·77; p=8·3×10−3). In late-onset bortezomib-induced peripheral neuropathy, the significant genes were SOD2 (upregulated by 1·18 times; p=9·6×10−3) and MYO5A (1·93 times; p=3·2×10−2), involved in development and function of the nervous system. Significant SNPs were noted in inflammatory genes MBL2 (OR 0·49, 95% CI 0·26-0·94; p=3·0×10−2) and PPARD (0·35, 0·15-0·83; p=9·1×10−3), and DNA repair genes ERCC4 (2·74, 1·56-4·84; p=1·0×10−3) and ERCC3 (1·26, 0·75-2·12; p=3·3×10−3). By contrast, early-onset vincristine-induced peripheral neuropathy was characterised by upregulation of genes involved in cell cycle and proliferation, including AURKA (3·31 times; p=1·04×10−2) and MKI67 (3·66 times; p=1·82×10−3), and the presence of SNPs in genes involved in these processes—eg, GLI1 (rs2228224 [0·13, 0·02-0·97, p=1·18×10−2] and rs2242578 [0·14, 0·02-1·12, p=3·00×10−2]). Late-onset vincristine-induced peripheral neuropathy was associated with the presence of SNPs in genes involved in absorption, distribution, metabolism, and excretion—eg, rs1413239 in DPYD (3·29, 1·47-7·37, 5·40×10−3) and rs3887412 in ABCC1 (3·36, 1·47-7·67, p=5·70×10−3). - Interpretation - Our results strongly suggest an interaction between myeloma-related factors and the patient's genetic background in the development of treatment-induced peripheral neuropathy, with different molecular pathways being implicated in bortezomib-induced and vincristine-induced peripheral neuropathy. - Funding - German Federal Ministry of Education and Research, Dutch Cancer Foundation Queen Wilhelmina, European Hematology Association, International Myeloma Foundation, Erasmus MC, and Janssen-Cilag Orthobiotech. | ||
| 700 | 1 | |a Corthals, Sophie L |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jongen, Joost LM |e VerfasserIn |4 aut | |
| 700 | 1 | |a van der Holt, Bronno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuiper, Rowan |e VerfasserIn |4 aut | |
| 700 | 1 | |a de Knegt, Yvonne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Duin, Mark van |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jarari, Laila el |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Lokhorst, Henk M |e VerfasserIn |4 aut | |
| 700 | 1 | |a Durie, Brian G |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Sonneveld, Pieter |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 11(2010), 11, Seite 1057-1065 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma a prospective analysis of data from the HOVON-65/GMMG-HD4 trial |
| 773 | 1 | 8 | |g volume:11 |g year:2010 |g number:11 |g pages:1057-1065 |g extent:9 |a Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma a prospective analysis of data from the HOVON-65/GMMG-HD4 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(10)70206-0 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1470204510702060 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230301 | ||
| 993 | |a Article | ||
| 994 | |a 2010 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 12 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 9 | ||
| 999 | |a KXP-PPN1837854092 |e 4282255102 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Annemiek","role":"aut","family":"Broyl","display":"Broyl, Annemiek"},{"given":"Sophie L","role":"aut","display":"Corthals, Sophie L","family":"Corthals"},{"display":"Jongen, Joost LM","family":"Jongen","role":"aut","given":"Joost LM"},{"display":"van der Holt, Bronno","family":"van der Holt","given":"Bronno","role":"aut"},{"given":"Rowan","role":"aut","display":"Kuiper, Rowan","family":"Kuiper"},{"display":"de Knegt, Yvonne","family":"de Knegt","role":"aut","given":"Yvonne"},{"display":"Duin, Mark van","family":"Duin","given":"Mark van","role":"aut"},{"family":"Jarari","display":"Jarari, Laila el","given":"Laila el","role":"aut"},{"given":"Uta","role":"aut","display":"Bertsch, Uta","family":"Bertsch"},{"display":"Lokhorst, Henk M","family":"Lokhorst","role":"aut","given":"Henk M"},{"family":"Durie","display":"Durie, Brian G","given":"Brian G","role":"aut"},{"role":"aut","given":"Hartmut","display":"Goldschmidt, Hartmut","family":"Goldschmidt"},{"given":"Pieter","role":"aut","display":"Sonneveld, Pieter","family":"Sonneveld"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma","title_sort":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma","subtitle":"a prospective analysis of data from the HOVON-65/GMMG-HD4 trial"}],"note":["Gesehen am 01.03.2023"],"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"21 September 2010"}],"id":{"eki":["1837854092"],"doi":["10.1016/S1470-2045(10)70206-0"]},"recId":"1837854092","relHost":[{"part":{"volume":"11","extent":"9","year":"2010","pages":"1057-1065","text":"11(2010), 11, Seite 1057-1065","issue":"11"},"titleAlt":[{"title":"The lancet <London> / Oncology"}],"language":["eng"],"disp":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma a prospective analysis of data from the HOVON-65/GMMG-HD4 trialThe lancet. Oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"2000","publisher":"The Lancet Publ. Group","dateIssuedDisp":"2000-","publisherPlace":"London"}],"note":["Gesehen am 22.09.2021"],"pubHistory":["0.2000 -"],"title":[{"title_sort":"lancet","partname":"Oncology","title":"The lancet"}],"id":{"issn":["1474-5488"],"zdb":["2035574-9"],"eki":["325349770"]},"recId":"325349770","physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"9 S."}],"name":{"displayForm":["Annemiek Broyl, Sophie L Corthals, Joost LM Jongen, Bronno van der Holt, Rowan Kuiper, Yvonne de Knegt, Mark van Duin, Laila el Jarari, Uta Bertsch, Henk M Lokhorst, Brian G Durie, Hartmut Goldschmidt, Pieter Sonneveld"]}} | ||
| SRT | |a BROYLANNEMMECHANISMS2120 | ||